Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798027 | 0.90 | HRH3 (0.69) | SIGMAR1HRH3ACHETEAD1MEN1 | |
| SCHEMBL798068 | 0.86 | HRH3 (0.58) | SIGMAR1HRH3TEAD1HRH4HSD11B1 | |
| SCHEMBL12891076 | 0.83 | ALDH1A1 (0.53) | SIGMAR1TEAD1MEN1KMT2AMCHR1 | |
| SCHEMBL12449569 | 0.83 | ALDH1A1 (0.53) | SIGMAR1TEAD1MEN1KMT2AMCHR1 | |
| SCHEMBL5824701 | 0.83 | SIGMAR1 (0.52) | SIGMAR1HRH3ACHETEAD1MEN1 | |
| SCHEMBL13215734 | 0.81 | HRH3 (0.61) | HRH3ACHEHRH4MEN1KMT2A | |
| SCHEMBL13727089 | 0.81 | HRH3 (0.61) | HRH3ACHEHRH4MEN1KMT2A | |
| SCHEMBL19107773 | 0.81 | HRH3 (0.61) | HRH3ACHEHRH4MEN1KMT2A | |
| SCHEMBL20232771 | 0.81 | HRH3 (0.61) | SIGMAR1HRH3ACHEHRH4MEN1 | |
| SCHEMBL12449571 | 0.81 | SIGMAR1 (0.48) | SIGMAR1TEAD1MEN1KMT2AMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802663-B2 | Pyrazole oxadiazole derivatives as S1P1 agonists | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20120071460-A1 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS | MERCK SERONO SA (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071460-A1 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS | S1PR1, S1PR3, S1PR2 | SIGMAR1 501/4885HRH3 196/4885ACHE 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.